EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
The study found that through 24 months, postmenopausal women with osteoporosis in the EVENITY treatment group experienced a statistically significant 48.0 percent relative reduction in the risk of a new vertebral (spine) fracture compared with those receiving alendronate alone (6.2 percent versus 11.9 percent, respectively [p<0.001]). At primary analysis, women in the EVENITY treatment group also experienced a statistically significant 27.0 percent relative reduction in the risk of clinical fracture, which includes non-vertebral fracture and clinical vertebral fracture (9.7 percent versus 13.0 percent, respectively [p<0.001]).
"The ARCH study shows that romosozumab can provide superior fracture risk reduction over alendronate, a commonly used, first-line osteoporosis treatment," said study lead author
At primary analysis, postmenopausal women in the EVENITY treatment group experienced a statistically significant 19.0 percent relative reduction in the risk of non-vertebral fractures (8.7 percent versus 10.6 percent, respectively [p=0.04]). A 38.0 percent relative reduction in the risk of hip fractures was also observed (2.0 percent versus 3.2 percent, respectively [nominalp=0.015]), when compared to those receiving alendronate alone.
Postmenopausal women who received EVENITY achieved greater gains in bone mineral density (BMD) from baseline at all measured sites and at all time points of the study versus those receiving alendronate alone. At month 12, the percentage change from baseline was greater with EVENITY versus alendronate at the lumbar spine (13.7 percent versus 5.0 percent, respectively [p<0.001]) and total hip (6.2 percent versus 2.8 percent, respectively [p<0.001]). In a subset of patients assessed every six months, significant gains were observed beginning at month six (p<0.001) for all sites.
Overall, adverse events and serious adverse events were generally similar between the treatment groups. An imbalance in adjudicated cardiovascular serious adverse events was observed during the 12-month period in 50 patients (2.5 percent) treated with EVENITY versus 38 patients (1.9 percent) treated with alendronate, with cardiac ischemic events and cerebrovascular events accounting for the imbalance.
The percentage of patients with adverse events and serious adverse events throughout the study as well as in the initial 12-month EVENITY treatment period were balanced between the groups, including incidences of osteoarthritis, hypersensitivity, cancer and hypocalcemia. Injection site reactions, mostly mild in severity, were reported in 4.4 percent of patients in the EVENITY treatment group and 2.6 percent in the alendronate group during the initial 12-month period.
During the open-label alendronate period, there were two positively adjudicated events of osteonecrosis of the jaw, one in a patient treated with EVENITY followed by alendronate and one treated with alendronate alone. There were six patients with positively adjudicated events of atypical femoral fracture during the open-label alendronate period, two patients treated with EVENITY followed by alendronate and four treated with alendronate alone.
About the ARCH Study
ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) is a Phase 3 multicenter, international, randomized, double-blind, alendronate-controlled study of EVENITY in 4,093 postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.
Patients were randomized 1:1 to receive either 210 mg EVENITY subcutaneously every month or 70 mg alendronate orally every week for the duration of the 12-month double-blind alendronate-controlled study period. After the double-blind active-comparator study period, patients received alendronate while remaining blinded to their initial treatment assignment. The incidence of new vertebral fracture was assessed at 24 months. The incidence of clinical fracture was assessed at the primary analysis, when 330 clinical fractures occurred or the last patient was on the study for 24 months, whichever was later. In addition, other key fracture endpoints including non-vertebral fracture and hip fracture were assessed at primary analysis.
About EVENITY™* (romosozumab)
EVENITY is an investigational bone-forming monoclonal antibody and is not approved by any regulatory authority for the treatment of osteoporosis. It is designed to work by inhibiting the activity of sclerostin, which enables EVENITY to rapidly increase bone formation and reduce bone resorption simultaneously. EVENITY is being studied for its potential to reduce the risk of fractures in an extensive global Phase 3 program. This program includes two large fracture trials comparing EVENITY to either placebo or active comparator in more than 10,000 postmenopausal women with osteoporosis.
About Osteoporosis
Osteoporosis is a condition that weakens bone over time, making them thinner, more brittle and more likely to break.1 Patients who experience an osteoporotic fracture are twice as likely to suffer a future fracture, yet more than 80 percent of fractures are not treated for underlying osteoporosis.2
About the
Since 2004,
About
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
About UCB
UCB,
This news release contains forward-looking statements that are based on the current expectations and beliefs of
No forward-looking statement can be guaranteed and actual results may differ materially from those
The scientific information discussed in this news release related to
UCB Forward-Looking Statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
CONTACT:
CONTACT: UCB, Brussels
T +32.2.559.9178, [email protected]
T+447702777378, [email protected]
T+32.2.559.92.64, [email protected]
T +32.2.559.94.14, [email protected]
T+32.2.559.9588, [email protected]
*The trade name EVENITY™ is provisionally approved for use by the
International Osteoporosis Foundation . What Is Osteoporosis? 2015. Available at: http://www.iofbonehealth.org/what-is-osteoporosis. AccessedAugust 4, 2017 .International Osteoporosis Foundation . Stop at One. One Fracture Leads to Another. http://share.iofbonehealth.org/WOD/2012/patient_brochure/WOD12-patient_brochure.pdf. Accessed August 4, 2017.
View original content with multimedia:http://www.prnewswire.com/news-releases/evenity-romosozumab-arch-study-results-published-in-the-new-england-journal-of-medicine-300517290.html
SOURCE
White House: Trump Was ‘Right’ To Fire Comey From FBI
Smucker’s constituents deserve better
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News